Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | EBV-lymphoma treatments on the horizon

Pierluigi Porcu • 6 Dec 2020
ASH 2020
Lymphoma CAR-T

Epstein–Barr virus (EBV)-related lymphomas are a heterogeneous group of hematologic malignancies that all harbor latent EBV within tumor cells. Pierluigi Porcu, MD, Sidney Kimmel Cancer Center, Philadelphia, PA, talks on what we can look forward to in terms of treatment for EBV-lymphomas in 2021, highlighting the use of CAR-T. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Pierluigi Porcu

2:49
Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD
Pierluigi Porcu • 16 Jun 2023
3:00
The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges
Pierluigi Porcu • 16 Jun 2023
3:18
Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial
Pierluigi Porcu • 16 Jun 2023
4:17
Nanatinostat and valganciclovir for EBV-associated lymphoma
Pierluigi Porcu • 6 Dec 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals